The global antibody drug conjugate market is expected to reach USD 7.72 billion by 2023 and is anticipated to grow at a CAGR of 9.63% during the forecast period 2023-2035

Antibody drug conjugates (ADCs) are a class of engineered therapeutics that combine monoclonal antibodies with potent cytotoxic payloads through specialized chemical linkers. These innovations have propelled ADCs into the spotlight as potent treatments for a broad spectrum of conditions, including solid tumors and hematological malignancies. This is owing to advancements in antibody engineering, which facilitate site-specific conjugation and improve pharmacokinetic and pharmacodynamic characteristics. Presently, the USFDA has approved 14 antibody-drug conjugates for therapeutic application, such as ado-trastuzumab emtansine (Kadcyla), brentuximab vedotin (Adcetris), inotuzumab ozogamicin (Besponsa), gemtuzumab ozogamicin (Mylotarg), and others.

The notable success of ADC therapeutics can be attributed to their exceptional tumor selectivity and potent cell-killing abilities, while effectively limiting off-target toxicities. Ongoing advancements in this field are fueled by promising outcomes from previous clinical trials, particularly focusing on various solid tumor types. With continued innovation, strong financial backing from investors, and encouraging clinical trial results, the market for antibody drug conjugates is poised for significant expansion in the projected period.

Report Coverage
? The report conducts an analysis of the antibody drug conjugates market, focusing on target disease indications, therapeutic areas, linkers, payloads, target antigens, and key geographical regions.
? Examination of market growth factors?drivers, restraints, opportunities, and challenges?to understand their impact on the industry’s development.
? Evaluation of potential advantages and obstacles within the market, providing insights into the competitive landscape for leading market players.
? Revenue forecasting for market segments across three major regions to gauge market potential and growth prospects.
? Concise presentation of research insights to encapsulate the current status and future trajectory of the antibody drug conjugate market.
? Introduction to antibody drug conjugates, encompassing their historical background, structural aspects, advantages, and pharmacokinetic properties.
? Comprehensive assessment of the market landscape, analyzing nearly 400 antibody drug conjugates in terms of their developmental status, disease indications, therapeutic areas, treatment lines, dosing frequencies, therapy types, target antigens, antibody types, payloads, linkers, and developer information.
? Insightful competitiveness analysis of biological targets using three-dimensional bubble representations and six-dimensional spider-web analysis, evaluating parameters such as development stages, therapy numbers, and indications.
? Detailed profiles of leading antibody drug conjugate companies based on 2022 sales revenue, including company overviews, financial information (if available), product portfolios, recent developments, and future outlooks.
? In-depth profiles of marketed ADC therapeutics, detailing their mechanisms of action, target antigens, linkers, payloads, therapy types, and sales data (if applicable).
? Analysis of completed, ongoing, and planned clinical studies on ADCs, covering parameters like trial registration, phases, patient populations, sponsors, study designs, industry players, non-industry participants, and geographical regions.
? Assessment of key opinion leaders (KOLs) involved in ADC-related clinical trials, considering KOL types, qualifications, affiliations, geographical locations, and prominent figures based on proprietary and third-party criteria.
? Analysis of therapeutics in combination with ADCs across various indications and their potential evolution.
? Detailed examination of partnerships formed in the ADC industry since 2014, focusing on partnership types, purposes, partner types, active players, and regional distributions.
? Examination of funding and investments in the ADC domain since 2014, covering financing types, amounts invested, leading companies, investors, and geographical analyses.
? In-depth analysis of ADC-related patents, including types, publication years, geographical locations, player types, assigned CPC symbols, organizations, and valuation assessments.
? Study of grants awarded to research institutes engaged in ADC-related research since 2016, considering grant details, funding institutes, support periods, grant purposes, popular NIH departments, recipient organizations, and key regions.
? Discussion on commercialization strategies pre, during, and post-launch of ADC products, featuring a framework outlining necessary steps and guidelines.
? Analysis of promotional strategies employed by developers of marketed ADC products, examining approaches used for products like Adcetris, Besponsa, Enhertu, etc.
? Success protocol analysis of recently approved ADC therapeutics based on parameters such as dosing frequency, efficacy, exclusivity, competition, prevalence, pricing, therapy type, and developer competition
? Overview of conjugation and linker technologies utilized in ADC development.
? Analysis of non-clinical data supporting First-In-Human (FIH) dose selection in ADCs, including findings from animal studies and methods for estimating FIH doses.
? Discussion on factors influencing ADC pricing, presenting different pricing approaches for pharmaceutical companies in determining prices for their lead therapy candidates.
? Case studies on ADC manufacturing challenges and contract service providers, alongside companion diagnostic companies offering tests for ADC treatment decisions.
? Exploration of industry evolution through SWOT analysis, assessing trends, drivers, challenges, and their relative impact on the overall industry landscape.

Key Market Companies
? ADC Therapeutics
? Astellas Pharma
? AstraZeneca
? Byondis
? Daiichi Sankyo
? Genentech
? Gilead Sciences
? ImmunoGen
? Pfizer
? RemeGen